<DOC>
	<DOCNO>NCT00987935</DOCNO>
	<brief_summary>This study evaluate safety , appropriate dose , efficacy BIBF 1120 liver cancer patient</brief_summary>
	<brief_title>A Phase I / II Trial Nintedanib Asian Hepatocellular Carcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : 1 . Hepatocellular carcinoma , either histologically/cytologically confirm clinically diagnose , amenable curative surgery locoregional therapy 2 . Age 18 year old 3 . Eastern Cooperative Group performance score 2 less 4 . ChildPugh score 7 less 5 . Written inform consent accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) local legislation Exclusion criterion : 1 . Prior systemic therapy metastatic/unresectable hepatocellular carcinoma ( phase II ) 2 . More one line prior systemic therapy metastatic/unresectable hepatocellular carcinoma ( phase I ) 3 . Uncontrolled refractory ascites adequate medical therapy 4 . Bilirubin great 1.5 time upper limit normal 5 . Aspartate amino transferase alanine amino transferase great 5 time upper limit normal 6 . Absolute neutrophil count less 1500/microliter 7 . Platelet count less 75000/microliter 8 . Hemoglobin le 9 g/dL 9 . Serum creatinine great 1.5 time upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>